Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
WORKING PAPERS
April 23, 2019
With the goal of driving down drug costs, governments across the globe have instituted various forms of pharmaceutical price control policies. In this paper, we examine the theoretical and empirical effects of one implementation of pharmaceutical price controls, in which the Indian government placed...
CGD NOTES
April 08, 2019
Criticising cancer medicine pricing as too high is what football fans know as an "open goal"—a target that is hard to miss. Yet somehow the World Health Organization Technical Report on Cancer Pricing manages to do just that with a paper to the WHO Executive Board calling for pri...
WORKING PAPERS
April 03, 2019
This paper focuses on the role that price transparency may play in the efficient and effective procurement of medicines by middle- and low-income countries. Will making prices publicly available make procurement more efficient and cost-effective medicines more accessible? We conclude that transparen...
Blog Post
March 26, 2019
At the end of 2018, the world had seven development impact bonds (DIBs) and more in the pipeline. Yet questions remain about the potential of DIBs—still a new financing instrument—compared to other pay-for-performance arrangements. With a dearth of standard and transparent evaluation met...
Blog Post
February 04, 2019
As countries strive to achieve the Sustainable Development Goals, including attaining and sustaining universal health coverage, decision-makers are increasingly using economic evaluation to drive macro policy choices and more granular technology-focused decisions. In a recent study, we discuss ...
Blog Post
December 03, 2018
On World AIDS Day, December 1, we honor the advocates that transformed HIV/AIDS from a death sentence to a chronic disease. These activists bequeathed a golden age of global health—a boom in money and programs that is sustained today, evidenced by the recent reauthorization of PEPFAR. But...
Blog Post
November 13, 2018
Back in February, the US Council of Economic Advisers issued a white paper on drug pricing implying that other rich countries should stop “free riding” off American innovation by negotiating drug prices to unfairly low levels after the US fronts the research and development cos...
Blog Post
June 11, 2018
The last several years have seen the development of many decision-support tools (“value frameworks”) for supporting policy and investment decisions. These tools make use of lots of numbers representing factors of undoubted importance in decision making, and they synthesise this informati...
CGD NOTES
May 14, 2018
This brief essay explores a key but often overlooked hurdle to using blockchain solutions, which is the complexity that decentralized solutions necessarily introduce. At times, the benefits of such solutions appear to exceed the added cost of complexity but often they do not. With this tradeoff in m...